Morgan Stanley’s Estrella Immunopharma ESLA Stock Holding History

Morgan Stanley’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$1	–	8471
2026 Q1	$1	Sell	1 -11,096	-100%	-$12.8K	﹤0.01%	8277
2025 Q4	$17.3K	Buy	+11,097	New	+$21K	﹤0.01%	6741

Other funds holding ESLA

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley's ESLA Position: Q2 2026 in Review

Morgan Stanley sold out of Estrella Immunopharma (ESLA) in Q2 2026, closing a stake of 1 share — an estimated $1 sold.

Morgan Stanley first reported a position in ESLA in Q4 2025 and held it in 2 quarters. The position peaked at $17.3K in Q4 2025. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

Morgan Stanley reported no remaining Estrella Immunopharma position as of Q2 2026 after selling out during the quarter.
Morgan Stanley sold 1 Estrella Immunopharma share in Q2 2026, an estimated $1.
Morgan Stanley first reported a position in Estrella Immunopharma in Q4 2025 and held it in 2 quarters.
Morgan Stanley's Estrella Immunopharma position peaked at $17.3K in Q4 2025.
15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.